Agency

Four Stagwell (STGW) Agencies - 72andSunny, Code and Theory, Colle McVoy and Team Epiphany - Awarded 2024 Ad Age Agency A-List Recognition for Business and Creative Transformation

Retrieved on: 
Monday, March 11, 2024
American Express, Business Transformation Agency, Oscar the Grouch, Cub Cadet, Amazon, Coca-Cola, National Football League, Exponentiation, Partnership, Digital, Hoorae Media, SMS, Yeezy, Sesame Street, DTC, Agency, La-Z-Boy, Super Bowl, Perdue, HBO, Bowl game, Marketing, NFL, Stagwell, Olympic, Advertising, Blizzard Entertainment, Sales

NEW YORK, March 11, 2024 /PRNewswire/ -- Stagwell (NASDAQ: STGW), the challenger network built to transform marketing, today celebrates four of its agencies recognized in Ad Age's 2024 Agency A-List: 72andSunny , Code and Theory , Colle McVoy and Team Epiphany .

Key Points: 
  • NEW YORK, March 11, 2024 /PRNewswire/ -- Stagwell (NASDAQ: STGW), the challenger network built to transform marketing, today celebrates four of its agencies recognized in Ad Age's 2024 Agency A-List: 72andSunny , Code and Theory , Colle McVoy and Team Epiphany .
  • Stagwell celebrates four of its agencies recognized in Ad Age's 2024 Agency A-List.
  • The Agency A-List is an annual ranking of the top agencies, companies, and innovators, honoring the best work and brightest ideas in advertising, marketing and the expanding innovation landscape.
  • "Congratulations to the teams at 72andSunny, Code and Theory, Colle McVoy and Team Epiphany for well-deserved recognition after another year of digital and creative innovation," said Stagwell Chairman and CEO Mark Penn.

American Canadian School of Medicine (ACSOM) Receives ECFMG Recognition and Sponsorship, Allowing Graduates to Take USMLE and Participate in NRMP

Retrieved on: 
Monday, March 11, 2024
Medical education, OSCE, Medical Council of Canada, ACCM, NAC, IAAR, Accreditation, Agency, College, WFME, USMLE, Stable marriage problem, Faculty, Student, World government, ECFMG, International medical graduate, NRMP, School, Nursing

PORTSMOUTH, Dominica, March 11, 2024 /PRNewswire-PRWeb/ -- The American Canadian School of Medicine (ACSOM) is proud to announce that it has been granted recognition and sponsorship by the Educational Commission for Foreign Medical Graduates (ECFMG). This significant achievement now allows ACSOM graduates to take the United States Medical Licensing Examination (USMLE) and participate in the National Resident Matching Program (NRMP). Canadians Students Eligible For Medical Council of Canada Qualifying Examination (MCCQ) part 1/ National Assessment Collaboration (NAC), Objective Structured Clinical Examination (OSCE) and Canadian Resident Matching Service (caRMS) match.

Key Points: 
  • The American Canadian School of Medicine (ACSOM) is proud to announce that it has been granted recognition and sponsorship by the Educational Commission for Foreign Medical Graduates (ECFMG).
  • This significant achievement now allows ACSOM graduates to take the United States Medical Licensing Examination (USMLE) and participate in the National Resident Matching Program (NRMP).
  • PORTSMOUTH, Dominica, March 11, 2024 /PRNewswire-PRWeb/ -- The American Canadian School of Medicine (ACSOM) is proud to announce that it has been granted recognition and sponsorship by the Educational Commission for Foreign Medical Graduates (ECFMG).
  • This significant achievement now allows ACSOM graduates to take the United States Medical Licensing Examination (USMLE) and participate in the National Resident Matching Program (NRMP).

Herbal medicinal product: Verbasci flosArray, C: ongoing call for scientific data

Retrieved on: 
Wednesday, April 3, 2024
Verbascum, Patient, Monograph, Committee, Sore throat, Herbal medicine, Date, Plant, Agency, Flower, Medicine

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of mullein flower.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing mullein flower.
  • These mullein flower medicines may also be found in combination with other herbal substances in some herbal medicines.
  • Key facts
    - Latin name
    - Verbasci flos
    - English common name
    - Mullein Flower
    - Botanical name
    Verbascum thapsus L.; V. densiflorum Bertol.

Herbal medicinal product: Vitis viniferae foliumArray, C: ongoing call for scientific data

Retrieved on: 
Wednesday, April 3, 2024
Community, Hypersensitivity, Chronic venous insufficiency, Weight, Cramp, Vein, Health, System, Varicose veins, Headache, Patient, Monograph, Committee, Hemorrhoid, Fatigue, Herbal medicine, Date, Allergy, Itch, Commission, Venous insufficiency, Nausea, Agency, Mouth, Skin, Water, Safety, Pain, Stomach, Medicine, Dietary supplement

Herbal medicinal product: Vitis viniferae foliumArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Vitis viniferae foliumArray, C: ongoing call for scientific data

Withdrawn application: Adcetris, 23/02/2024

Retrieved on: 
Wednesday, April 3, 2024
PTCL-NOS, Lymphoma, B-cell lymphoma, CHOP, Patient, PTCL, Doxorubicin, Vincristine, CHP, Cancer, Vinblastine, European Medicines Agency, CTCL, Prednisone, Lymphocyte, Agency, Clinical trial, Skin, Dacarbazine, CD30, Cyclophosphamide, Medicine

Adcetris was designated an ‘orphan medicine’ (a medicine used in rare diseases) for peripheral T cell lymphoma 21 August 2019.

Key Points: 
  • Adcetris was designated an ‘orphan medicine’ (a medicine used in rare diseases) for peripheral T cell lymphoma 21 August 2019.
  • The cytotoxic molecule then enters the cancer cells and prevents them from dividing, causing the cancer cells to die.
  • The application was withdrawn after the European Medicines Agency had evaluated the initial information from the company and had prepared questions for the company.
  • If you are in a clinical trial and need more information about your treatment, speak with your clinical trial doctor.

Withdrawn application: Orencia, 19/02/2024

Retrieved on: 
Wednesday, April 3, 2024
CD86, Graft-versus-host disease, Gene, Methotrexate, Psoriasis, Letter, Cell, Bone marrow, Risk, Inflammation, Patient, Ageing, Psoriatic arthritis, HSCT, Allele, Joint, Protein, HLA, European Medicines Agency, Arthritis, Syringe, Rheumatism, Agency, Clinical trial, Skin, CD80, Cancer, Immune system, Blood, Calcineurin, Medicine, Vaccine

Withdrawn application: Orencia, 19/02/2024

Key Points: 


Withdrawn application: Orencia, 19/02/2024

Procedural advice for orphan medicinal product designation: Guidance for sponsors

Retrieved on: 
Wednesday, April 3, 2024
Community, Reproduction, Letter, European Commission, European Communities, Inn, Patient, Agency, Translation, European Medicines Agency, Council, European, Deference, VSI, Marketing, Legislation, Certification, MHLW, Annex, European Economic Area, PDF, Public, Medication, Committee, Policy, Bibliography, EMA, CAT, COMP, SME, Language, Ministry, CHMP, Decision, Cisco Webex, Prevalence, Disease, Part, Classification, Regulation (European Union), Privacy, Commission, RTF, EEA, Sponsor, PMDA, FDA, Guideline, Diagnosis, Civil service commission, European Council, European Parliament, Recognition, Art, INN, Official Journal, Record, TEAMS, Mutual, Microsoft PowerPoint, ID, Pharmaceutical industry

Frequently asked questions ................................................................... 10

Key Points: 
    • Frequently asked questions ................................................................... 10

      Procedural advice for orphan medicinal product designation
      EMA/420706/2018

      Page 2/13

      1.

    • This Regulation lays down the procedure for
      the designation of medicinal products as orphan medicinal products and provides incentives for the
      development and placing on the market of designated orphan medicinal products.
    • The Regulation also
      establishes the Committee for Orphan Medicinal Products (COMP) within the European Medicines
      Agency (EMA), which is responsible for examining applications for orphan medicinal product
      designation.
    • As of 28 April 2000, the date this Regulation entered into force, sponsors have been able to
      submit applications for orphan medicinal product designation to the EMA.
    • Procedural advice for orphan medicinal product designation
      EMA/420706/2018

      Page 3/13

      2.

    • Objectives
      In examining an application for orphan medicinal product designation, the COMP will focus on
      determining whether the sponsor has established that the designation criteria are met, i.e.
    • To assist in the development of a policy on orphan medicinal products, an expert network will
      be built up by the Committee, with expert(s) identified as appropriate to be involved in the evaluation
      of applications for orphan medicinal product designation.
    • ?

      The complete application should include:

      Procedural advice for orphan medicinal product designation
      EMA/420706/2018

      Page 5/13

      Document

      Format

      General administrative and scientific information completed online via the portal.

    • Important:
      In preparing an application for orphan medicinal product designation, sponsors are requested to follow
      the Commission guideline (2022/C 440/02) on the format and content of applications for designation
      as orphan medicinal products.
    • Please refer to the Procedural advice on
      appeal procedure for Orphan Medicinal Product Designation (EMEA/2677/01 Rev.3).
    • The grounds for the

      Procedural advice for orphan medicinal product designation
      EMA/420706/2018

      Page 9/13

      appeal should be based only on the original information provided in the application for orphan
      designation.

    • ?

      The European Commission will enter the designated medicinal product in the Community Register
      of Orphan Medicinal Products.

    • General advice
      ?

      Full information on the procedure for orphan medicinal products designation is available on the
      EMA orphan designation website.

    • In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the sponsor may submit an
      application for orphan medicinal product designation to the Agency at any stage of development of the

      Procedural advice for orphan medicinal product designation
      EMA/420706/2018

      Page 10/13

      medicinal product as long as the criteria for designation may be justified.

    • A request for orphan medicinal product designation may be made for
      a new orphan indication for an already authorised medicinal product.
    • Procedural advice for orphan medicinal product designation
      EMA/420706/2018

      Page 11/13

      Which are the sponsor?s options in case of negative outcome for orphan designation?

Committee for Medicinal Products for Veterinary Use (CVMP): 12-14 March 2024, European Medicines Agency, Amsterdam, the Netherlands, from 12 March 2024 to 14 March 2024

Retrieved on: 
Wednesday, April 3, 2024
Committee, Medicine, Agency, CVMP, Vaccine

Committee for Medicinal Products for Veterinary Use (CVMP): 12-14 March 2024

Key Points: 

Committee for Medicinal Products for Veterinary Use (CVMP): 12-14 March 2024
EventVeterinaryMedicines
Date
Location
The Committee for Medicinal Products for Veterinary Use (CVMP) is the committee that is responsible for preparing the Agency's opinions on all questions concerning veterinary medicines.

Committee for Medicinal Products for Veterinary Use (CVMP): 13-15 February 2024, European Medicines Agency, Amsterdam, the Netherlands, from 13 February 2024 to 15 February 2024

Retrieved on: 
Wednesday, April 3, 2024
Committee, Medicine, Agency, CVMP

Committee for Medicinal Products for Veterinary Use (CVMP): 13-15 February 2024

Key Points: 

Committee for Medicinal Products for Veterinary Use (CVMP): 13-15 February 2024
The Committee for Medicinal Products for Veterinary Use (CVMP) is the committee that is responsible for preparing the Agency's opinions on all questions concerning veterinary medicines.
EventVeterinaryMedicines